EUFORYa
Track EU Parliament activity with clear, human-friendly updates.
Track EU Parliament activity with clear, human-friendly updates.
Cracking Down on Chemicals Used to Make Illegal Drugs
Published December 03, 2025
Goal: Stop illegal drugs
Community improvement
Clickbaity title? Suggest change
This new EU regulation merges old rules, creates a digital system to license and track dangerous chemicals, bans designer precursors unless licensed, and cuts paperwork for businesses.
Document summary The source
What the problem that is being addressed
- Illicit drug makers are increasingly using designer precursors ā chemicals that have no normal commercial use but can be turned into drugs.
- The two existing EU rules (Regulation (EC) No 273/2004 for the internal market and Regulation (EC) No 111/2005 for trade with third countries) are old, split, and create a lot of paperwork for businesses that sell or use these chemicals.
- The rules do not cover designer precursors well, and the administrative burden on operators and customs authorities is high.
How that problem is being solved here
- The two old regulations are merged into one new Regulation that covers both internal and external trade.
- Three new categories of precursors are defined:
- Category 1 ā the most dangerous chemicals (e.g., phenylacetone).
- Category 2 ā widely used chemicals that can still be diverted (e.g., red phosphorus, hydrochloric acid).
- Category 3 ā designer precursors that have no normal use except research.
- Designer precursors are now automatically banned unless a company gets a licence or gives a prior notification for research use.
- A centralised electronic system will let operators:
- apply for licences, registrations and prior notifications online.
- verify that their customers also have licences.
- report suspicious transactions, thefts or disappearances.
- notify customs of import/export quantities.
- Customs will use the same system to check licences and quantities before releasing goods.
- A Drug Precursors Information Repository will list all scheduled and nonāscheduled substances, their legitimate uses and how they can be used in drug production.
- The new rules remove the need for periodic reporting by operators and simplify many administrative steps.
What changes as a result of this document
| Item | Change | Numbers |
|---|---|---|
| Licences & registrations | Simplified, digital, fewer forms | 10 % rise in enforcement costs; oneāoff cost of ā¬7.7 million for operators to adjust to new rules |
| Administrative burden | Reduced by ā¬25.27 million per year (net saving) | 25.27 million ā¬ |
| Digital system | Built by DG GROW, linked to the EU Single Window for customs | ā¬1.322 million (internal market IT) + ā¬24.148 million (external trade IT) |
| Information repository | New database of all precursors | ā¬0.530 million |
| Transition period | 3 years after entry into force for full application | 3 years |
| Review | 10āyear evaluation of the Regulation | 10āyear review |
| SME impact | 92 % of the ~4 000 active licences are SMEs | 4 000 licences, 92 % SMEs |
| Budget | Total estimated cost for IT and repository over 2028ā2034 | ā¬26.427 million (IT) + ā¬0.530 million (repo) + ā¬24.148 million (external trade) ā ā¬51 million |
| Legal | Repeals Regulations (EC) No 273/2004 and (EC) No 111/2005 | ā |
| Scope | Covers all scheduled and nonāscheduled precursors, except for pharmacies, veterinary dispensaries and certain official authorities | ā |
The Regulation therefore tightens control of dangerous chemicals, speeds up customs checks, cuts paperwork for businesses, and creates a single digital platform that will make the EUās drugāprecursor system clearer and more efficient.
Licensing: This article is available under Creative Commons Attribution 4.0 (CC BY 4.0).